- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05891821
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.
Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.
Study Overview
Detailed Description
This is a single-arm, open-label phase 2 study to evaluate the safety and efficacy of single agent balstilimab in participants with relapsed/refractory lymphoma. The study will enroll participants with relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma. The participants will receive balstilimab (BAL) 300 mg IV every 3 weeks. BAL infusions will be administered within 30 minutes (± 5 min) using an infusion pump.
The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods:
- Screening Period: approximately 28 days
- Treatment Period: up to 24 months, or until any criterion for stopping the study drug or withdrawal from the study occurs
- Follow-up Period: up to 24 months from last dose of study treatment for every patient who is alive
Study Duration
- Recruitment: 2 years
- Treatment: 2 years
- Follow-up: 2 years
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Astghik Voskanyan, MD
- Phone Number: +374 (10) 283800
- Email: astghikvos@gmail.com
Study Contact Backup
- Name: Samvel Bardakhchyan, MD, PhD
- Phone Number: +374 (10) 283800
- Email: bardakchyan-5samvel@yandex.ru
Study Locations
-
-
-
Yerevan, Armenia, 0014
- Recruiting
- Hematology Center named after prof. R. Yeolyan
-
Contact:
- Astghik Voskanyan, MD
- Phone Number: +374 (010) 283800
- Email: astghikvos@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily agree to participate by giving written informed consent
- ≥ 18 years of age
- Have a histologically confirmed diagnosis of a relapsed/refractory classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL) for which no standard therapy is available or standard therapy has failed or the patient does not have access to it.
- Has a life expectancy of at least 3 months and an ECOG performance status of ≤1 as determined by study Investigator
- Patients must have sufficient and adequate formalin-fixed tumor tissue sample available that is not older than 3 years; otherwise, a fresh biopsy is required. Archival tissue or fresh biopsy must be from a site not previously irradiated
Has adequate organ function defined as the following laboratory values within 7 days of C1D1:
- Neutrophils ≥ 1500/μL (Must be stable and off any growth factor within 4 weeks of first study treatment administration)
- Platelets ≥ 75 × 103/μL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration)
- Hemoglobin ≥ 8.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration)
- Creatinine clearance ≥ 30 mL/min as measured or calculated per local institutional standards
- AST/ALT ≤ 3 × upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 × ULN (except patients with Gilbert syndrome who must have a total bilirubin level of ≤ 3.0 × ULN)
Women of childbearing potential (WOCP) must have a negative serum pregnancy test at Screening (within 7 days before first dose of study drug). Non-childbearing potential is defined as (by other than medical reasons):
- ≥ 50 years of age and has not menstruated for greater than 1 year
- Whose status is post hysterectomy, bilateral oophorectomy, or tubal ligation
- WOCP must be willing to use highly effective methods of contraception (defined in the informed consent form [ICF]) throughout the study, starting with the Screening Visit through 90 days after the last dose of study drug Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
- Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 90 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
- Is willing and able to comply with the requirements of the protocol
Exclusion Criteria:
Has an inadequate period of time prior to first dose of study treatment that is defined as:
- Received systemic cytotoxic chemotherapy within 3 weeks before initiation of study treatment
- Received biological therapy or investigational therapy within 4 weeks or 5 circulating halve-lives, whichever is shorter
- Received small molecule/tyrosine kinase inhibitors within 2 weeks or 5 circulating half-lives, whichever is shorter
- Received radiation therapy within 3 weeks before initiation of study treatment, except for palliative radiation therapy, which can be received 2 weeks prior to initiation of study treatment
- Had major surgery within 4 weeks before initiation of study treatment
Has gone through disease progression after receiving prior therapy with:
a. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-PD-1 and anti-PD-L1 antibodies
- Has persisting AEs related to prior immunotherapy of NCI-CTCAE v5.0 Grade ≥ 2 severity.
- Is expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent, radiation therapy, and/or surgical resection)
- Has known allergy or hypersensitivity to any component of balstilimab, any history of anaphylaxis, or uncontrolled asthma
- Has active or history of autoimmune disease that requires systemic treatment within 2 years of the start of study drug (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) Note: Patients with autoimmune conditions requiring hormone replacement therapy or topical treatments are eligible.
- Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
- Has had an allogeneic tissue/solid organ transplant
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ III), or serious uncontrolled cardiac arrhythmia requiring medication.
a. QTcF (QTc interval corrected using Fridericia's formula) of > 480 ms.
- Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.
- Has known untreated hepatitis B/hepatitis C virus (HBV/HCV) or tuberculosis. Active HBV is defined as a known positive hepatitis B surface antigen result. Active HCV is defined by a known positive hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay
- Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.
- Has other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study
- Has known psychiatric or substance use disorders that would interfere with cooperation or compromise participation with the requirements of the study
- Is legally incapacitated or has limited legal capacity
- Is pregnant or breastfeeding
- Has received a live/attenuated vaccine within 14 days of first dose of study treatment and other vaccines within 48 hours of first dose of study treatment
- Has other co-morbidities that would alter risk-benefit of providing balstilimab (determined by treating physician's assessment)
- Is receiving other therapy that would alter risk-benefit of providing balstilimab (determined by treating physician's assessment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Balstilimab
300 mg IV every 3 weeks for a maximum of 24 months
|
An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: First dose to up to 27 months
|
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) assessed per the Lugano criteria
|
First dose to up to 27 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: First dose to up to 27 months
|
DOR is defined as time from first observation of response to first observation of documented disease progression per the Lugano criteria or death within 12 weeks of last tumor assessment
|
First dose to up to 27 months
|
Disease Control Rate (DCR)
Time Frame: First dose to up to 27 months
|
DCR is defined as the percentage of patients who have achieved complete response, partial response or stable disease per the Lugano criteria
|
First dose to up to 27 months
|
Duration of Stable Disease (SD)
Time Frame: First dose to up to 27 months
|
Duration of SD is measured from the start of treatment until the criteria for progression are met, per the Lugano criteria
|
First dose to up to 27 months
|
Time to Response
Time Frame: First dose to up to 27 months
|
Time to Response is defined as the time from the first dose date to first observation of confirmed response per the Lugano criteria
|
First dose to up to 27 months
|
Progression-Free Survival (PFS) Time
Time Frame: First dose to up to 27 months
|
PFS time is defined as time from first treatment administration to first observation of documented disease progression (or death within 12 weeks after last tumor assessment), per the Lugano criteria
|
First dose to up to 27 months
|
Overall Survival (OS) Time
Time Frame: First dose to up to 48 months
|
OS Time is defined as time from start of treatment to death
|
First dose to up to 48 months
|
Baseline expression of PD-L1 association with ORR
Time Frame: First dose to up to 48 months
|
Tumor PD-L1 status will be determined and correlation with ORR will be investigated
|
First dose to up to 48 months
|
Baseline expression of PD-L1 association with DOR
Time Frame: First dose to up to 48 months
|
Tumor PD-L1 status will be determined and correlation with DOR will be investigated
|
First dose to up to 48 months
|
Baseline expression of PD-L1 association with PFS
Time Frame: First dose to up to 48 months
|
Tumor PD-L1 status will be determined and correlation with PFS time will be investigated
|
First dose to up to 48 months
|
Baseline expression of PD-L1 association with OS
Time Frame: First dose to up to 48 months
|
Tumor PD-L1 status will be determined and correlation with OS time will be investigated
|
First dose to up to 48 months
|
Frequency, severity, and duration of treatment emergent adverse events (TEAEs) and laboratory abnormalities
Time Frame: First dose to up to 27 months
|
TEAEs are reported using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
|
First dose to up to 27 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Samvel Bardakhchyan, MD, PhD, Immune Oncology Research Institute
- Study Director: Gevorg Tamamyan, MD, PhD, DSc, Immune Oncology Research Institute
- Principal Investigator: Astghik Voskanyan, MD, Hematology Center named after prof. R. Yeolyan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMMONC0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsTerminatedLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
Clinical Trials on Balstilimab
-
M.D. Anderson Cancer CenterAgenus Inc.RecruitingOropharyngeal Cancer | HPVUnited States
-
Targovax OyAgenus Inc.Withdrawn
-
Agenus Inc.Betta Pharmaceuticals Co., Ltd.Withdrawn
-
Agenus Inc.SuspendedAdvanced MelanomaUnited States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
-
Groupe Oncologie Radiotherapie Tete et CouRecruitingAdenoid Cystic Carcinoma of the Head and NeckFrance
-
Weill Medical College of Cornell UniversityAgenus Inc.Recruiting
-
Agenus Inc.RecruitingMelanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver MetastasesUnited States
-
Immune Oncology Research InstituteAgenus Inc.Not yet recruiting
-
Agenus Inc.Available
-
Agenus Inc.Terminated